Comparison of the tolerability, ease of use, and efficacy of donepezil and rivastigmine in Alzheimer's disease patients: A 12-week multinational study

被引：0
|
作者：
Wilkinson, DG
Passmore, P
Smith, R
Hock, C
Potonik, F
Maud, C
Hopker, S
机构：
来源：
NEUROLOGY | 2001年 / 56卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：A456 / A457
页数：2
相关论文
共 50 条
  • [21] Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil
    Auriacombe, S
    Pere, JJ
    Loria-Kanza, Y
    Vellas, B
    CURRENT MEDICAL RESEARCH AND OPINION, 2002, 18 (03) : 129 - 138
  • [22] Efficacy and safety of donepezil in patients with Alzheimer's disease - Results of a. global, multinational, clinical experience study
    Boada-Rovira, M
    Brodaty, H
    Cras, P
    Baloyannis, S
    Emre, M
    Zhang, R
    Bahra, R
    DRUGS & AGING, 2004, 21 (01) : 43 - 53
  • [23] Safety and Tolerability of Donepezil, Rivastigmine and Galantamine for Patients with Alzheimer's Disease: Systematic Review of the 'Real-World' Evidence
    Lockhart, I. A.
    Mitchell, S. A.
    Kelly, S.
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2009, 28 (05) : 389 - 403
  • [24] Tolerability, safety and efficacy in patients with Alzheimer's disease who are switched from donepezil to galantamine
    Kurz, AF
    Gold, M
    NEUROBIOLOGY OF AGING, 2004, 25 : S202 - S203
  • [25] Comments on efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil
    McRae, TD
    Schwam, EM
    CURRENT MEDICAL RESEARCH AND OPINION, 2002, 18 (06) : I - III
  • [26] Efficacy and Safety of Donepezil in Patients with Alzheimer’s DiseaseResults of a Global, Multinational, Clinical Experience Study
    Mercè Boada-Rovira
    Henry Brodaty
    Patrick Cras
    Stavros Baloyannis
    Murat Emre
    Richard Zhang
    Ranbir Bahra
    Drugs & Aging, 2004, 21 : 43 - 53
  • [27] Safety/Tolerability and Efficacy of Rivastigmine in Taiwanese Patients with Alzheimer's Disease A Prospective Post-Marketing Surveillance Study
    Chiu, Pai-Yi
    Dai, Dao-En
    Hsu, Hai-Pei
    Lee, Chao
    Lin, Juei-Jueng
    Kuo, Hung-Chou
    Huang, Ying-Chih
    Liu, Yung-Chang
    Tsai, Ching-Piao
    CLINICAL DRUG INVESTIGATION, 2009, 29 (11) : 729 - 738
  • [28] Effects of Donepezil, Galantamine and Rivastigmine in 938 Italian Patients with Alzheimer's Disease A Prospective, Observational Study
    Santoro, Aurelia
    Siviero, Paola
    Minicuci, Nadia
    Bellavista, Elena
    Mishto, Michele
    Olivieri, Fabiola
    Marchegiani, Francesca
    Chiamenti, Andrea Maria
    Benussi, Luisa
    Ghidoni, Roberta
    Nacmias, Benedetta
    Bagnoli, Silvia
    Ginestroni, Andrea
    Scarpino, Osvaldo
    Feraco, Emidio
    Gianni, Walter
    Cruciani, Guido
    Paganelli, Roberto
    Di Iorio, Angelo
    Scognamiglio, Mario
    Grimaldi, Luigi Maria Edoardo
    Gabelli, Carlo
    Sorbi, Sandro
    Binetti, Giuliano
    Crepaldi, Gaetano
    Franceschi, Claudio
    CNS DRUGS, 2010, 24 (02) : 163 - 176
  • [29] An investigation into the safety, tolerability, and efficacy of high dose rivastigmine treatment in Alzheimer's disease
    Shua-Haim, JR
    Pass, MD
    Patel, S
    Lee, P
    Patel, P
    NEUROBIOLOGY OF AGING, 2004, 25 : S196 - S196
  • [30] Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease
    Blesa, Rafael
    Bullock, Roger
    He, Yunsheng
    Bergman, Howard
    Gambina, Giuseppe
    Meyer, Joanne
    Rapatz, Guenter
    Nagel, Jennifer
    Lane, Roger
    PHARMACOGENETICS AND GENOMICS, 2006, 16 (11): : 771 - 774
12345